Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer epilepsy panel testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone781-430-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees44
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable
Stoke Therapeutics (NASDAQ:STOK) Frequently Asked Questions
What is Stoke Therapeutics' stock symbol?
Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."
How were Stoke Therapeutics' earnings last quarter?
Stoke Therapeutics (NASDAQ:STOK) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01. View Stoke Therapeutics' Earnings History.
When is Stoke Therapeutics' next earnings date?
What price target have analysts set for STOK?
6 analysts have issued 1-year price targets for Stoke Therapeutics' stock. Their forecasts range from $30.00 to $46.00. On average, they anticipate Stoke Therapeutics' stock price to reach $37.60 in the next twelve months. This suggests a possible upside of 57.9% from the stock's current price. View Analyst Price Targets for Stoke Therapeutics.
What is the consensus analysts' recommendation for Stoke Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stoke Therapeutics.
Has Stoke Therapeutics been receiving favorable news coverage?
News coverage about STOK stock has been trending negative recently, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Stoke Therapeutics earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Stoke Therapeutics.
Are investors shorting Stoke Therapeutics?
Stoke Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 849,400 shares, an increase of 5.3% from the October 31st total of 806,300 shares. Based on an average daily volume of 177,700 shares, the short-interest ratio is currently 4.8 days. Approximately 5.5% of the company's stock are short sold. View Stoke Therapeutics' Current Options Chain.
Who are some of Stoke Therapeutics' key competitors?
Some companies that are related to Stoke Therapeutics include Blueprint Medicines (BPMC), Evotec (EVTCY), Alkermes (ALKS), SAGE Therapeutics (SAGE), Myokardia (MYOK), Genmab A/S (GMAB), HUTCHISON CHINA/S (HCM), PTC Therapeutics (PTCT), GW Pharmaceuticals PLC- (GWPH), Deciphera Pharmaceuticals (DCPH), Biohaven Pharmaceutical (BHVN), Uniqure (QURE), Emergent Biosolutions (EBS), Agios Pharmaceuticals (AGIO) and Zai Lab (ZLAB).
What other stocks do shareholders of Stoke Therapeutics own?
Who are Stoke Therapeutics' key executives?
Stoke Therapeutics' management team includes the folowing people:
- Dr. Edward M. Kaye, CEO & Director (Age 70)
- Dr. Adrian R. Krainer, Co-Founder & Director (Age 60)
- Ms. Isabel Aznarez, Co-Founder, VP & Head of Biology
- Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer (Age 60)
- Dr. Huw M. Nash Ph.D., COO & Chief Bus. Officer (Age 52)
When did Stoke Therapeutics IPO?
(STOK) raised $100 million in an initial public offering (IPO) on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.
When does the company's lock-up period expire?
Stoke Therapeutics' lock-up period expires on Monday, December 16th. Stoke Therapeutics had issued 7,891,110 shares in its initial public offering on June 19th. The total size of the offering was $142,039,980 based on an initial share price of $18.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
Who are Stoke Therapeutics' major shareholders?
Stoke Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (5.73%), Redmile Group LLC (3.11%), Millennium Management LLC (2.13%), State Street Corp (0.42%), Squarepoint Ops LLC (0.07%) and Granite Point Capital Management L.P. (0.05%). Company insiders that own Stoke Therapeutics stock include Apple Tree Partners Iv, LP and Rtw Investments, Lp. View Institutional Ownership Trends for Stoke Therapeutics.
Which major investors are selling Stoke Therapeutics stock?
Which major investors are buying Stoke Therapeutics stock?
STOK stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Squarepoint Ops LLC, Gilder Gagnon Howe & Co. LLC, California State Teachers Retirement System, Barclays PLC and Strs Ohio. Company insiders that have bought Stoke Therapeutics stock in the last two years include Apple Tree Partners Iv, LP and Rtw Investments, Lp. View Insider Buying and Selling for Stoke Therapeutics.
How do I buy shares of Stoke Therapeutics?
Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Stoke Therapeutics' stock price today?
One share of STOK stock can currently be purchased for approximately $23.82.
How big of a company is Stoke Therapeutics?
What is Stoke Therapeutics' official website?
How can I contact Stoke Therapeutics?
Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]
MarketBeat Community Rating for Stoke Therapeutics (NASDAQ STOK)
MarketBeat's community ratings are surveys of what our community members think about Stoke Therapeutics and other stocks. Vote "Outperform" if you believe STOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
